Form 4: SpringWorks Therapeutics COO Sells Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
Badreddin Edris, Chief Operating Officer of SpringWorks Therapeutics, sold shares of common stock on June 3, 2024, under a pre-arranged trading plan.
Summary
- On June 3, 2024, Badreddin Edris, the Chief Operating Officer of SpringWorks Therapeutics, sold shares of the company's common stock.
- The sales were executed under a trading plan adopted on February 29, 2024, in accordance with Rule 10b5-1.
- A total of 19,992 shares were sold at weighted average prices ranging from $39.4015 to $42.0366.
- Following the reported transactions, Edris directly owns 249,600 shares of SpringWorks Therapeutics common stock.
Sentiment
Score: 5
Explanation: Neutral sentiment as the document simply reports stock sales under a pre-existing trading plan.
Industry Context
Insider sales are a common occurrence, and the use of a 10b5-1 trading plan suggests the sales were pre-planned and not based on any specific non-public information.
Stakeholder Impact
- The stock sale could have a minor negative impact on shareholder sentiment, although the existence of a 10b5-1 plan mitigates this concern.
- The sale does not appear to have any direct impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| February 29, 2024 | Date of adoption of the Rule 10b5-1 trading plan. |
| June 03, 2024 | Date of the stock sale transactions. |
| June 05, 2024 | Date of signature of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.